Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
... dihydrochloride) for the treatment of phenylketonuria (PKU). The patent for stable tablet formulation ... due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a ... )(sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck ...BioMarin Receives 2009 Corporate Award for the Development of Kuvan
... toward improving the lives of people living with phenylketonuria (PKU). NORD honored BioMarin for the ... due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). PKU is a rare genetic disorder that can ... Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck ...JCI online early table of contents: July 1, 2008
... Bringing stability to the protein defective in phenylketonuria phenylketonuria (PKU) is an inherited disease characterized by ... as potential therapeutic agents to treat phenylketonuria AUTHOR CONTACT: Aurora Martinez University ...BioMarin Announces Second Quarter 2009 Financial Results
... (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), was $16.9 million for the second quarter of 2009, compared to $12.0 ... Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck ...Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study
... (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). The company expects to initiate the Phase 2 clinical study in late ... Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck ...The National PKU Alliance Expands Leadership and Names Christine Brown as Executive Director
... dedicated to supporting those affected by the genetic disorder phenylketonuria (PKU), today announced that it has selected Christine Brown to be its ... Violence Coordinating Council in Maryland. About PKU PKU, or phenylketonuria (pronounced fen-il-Key-to-New-ree-uh ) is a lifelong genetic disorder in ...Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
... Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU). Kuvan was approved by the U.S. Food and Drug Administration (FDA) ... hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet. ...BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
... Darmstadt, Germany. Kuvan is an oral small molecule for the treatment of phenylketonuria (PKU) developed in partnership with Merck Serono. Based on published ... hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet. ...Meta-Analysis of Blood Phe Levels and Clinical Outcomes in PKU Published
... meta-analysis of blood phenylalanine (Phe) levels and clinical outcomes in phenylketonuria (PKU) was published in the September/October 2007 issue of Molecular ... dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in ...Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome
... developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL ...BioMarin Announces FDA Approval for Kuvan
... Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU). Shipments to the distribution channel will commence tomorrow, and ... hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet. ...Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
... with Kuvan results in significant reductions in blood Phe levels in some phenylketonuria (PKU) patients. Kuvan, an investigational oral small molecule for the ... dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in ...BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
... developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL ...BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
... Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease ...UW-Madison study reveals new options for people with PKU
... MADISON For people with the genetic condition known as phenylketonuria (PKU), diet is a constant struggle. They can eat virtually no protein, and instead get their daily dose of this key macronutrient by drinking a ...New drug holds out promise of normal diet for sufferers of devastating PKU genetic disease
... Margie Fischer doesn't have to imagine it; that was normal life at her family's dinner table for years. Her daughter Maggie, now 20, suffers from phenylketonuria (PKU), a genetic disease that means her body can't tolerate anything more than a low-protein diet. PKU is described by scientists as an autosomal ...Children's Memorial Hospital of Chicago receives a grant from BioMarin to support adult PKU outreach
... IL, Children's Memorial Hospital of Chicago announced today that it has received a grant from BioMarin Pharmaceutical Inc. to support its Adult phenylketonuria (PKU) Outreach Education Project. The goal of the program is to conduct outreach to PKU patients who are no longer being treated at PKU clinics to ...Nationwide Children's Hospital involved in expanded access program for treatment of PKU
... announced today its involvement in an expanded access program for sapropterin dihydrochloride, or sapropterin, an investigational treatment for phenylketonuria (PKU), a rare genetic metabolic disorder that, if left unmanaged in infants and children, can result in severe mental retardation. Currently, there ...Birth defects: 8 million annually worldwide
... with genetic disorders; Establish newborn screening programs to identify babies born with devastating but treatable metabolic disorders such as phenylketonuria (PKU); Educate women and men of childbearing age about how they can work with health professionals to maximize the chances of having a healthy ...Kuvan Receives Priority Review Status From Health Canada
... as an oral treatment for patients with phenylketonuria (PKU) from Health Canada. Priority review ... due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a ... (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck ...BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
... (sapropterin dihydrochloride) in the treatment of phenylketonuria (PKU). The company expects that the patent will ... due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a ... Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck ...BioMarin Announces First Quarter 2009 Financial Results
... (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), was $15.5 million for the first quarter of 2009, compared to $5.8 ... Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck ...BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
... (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), was $15.1 million for the fourth quarter of 2008 and $46.7 million ... Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck ...BioMarin Announces Third Quarter 2008 Financial Results
... (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), was $13.8 million for the third quarter of 2008 and $31.6 million ... Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck ...Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
... Labour and Welfare for approval of its BH4 product for the treatment of phenylketonuria (PKU) in Japan. The application is for a label extension for its current ... dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in ...BioMarin to Present at the Jefferies Healthcare Conference
... a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL ...BioMarin to Present at the Goldman Sachs Healthcare Conference
... a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL ...